Rodman & Renshaw Reiterates Geron Market Outperform, $9 PT

Rodman & Renshaw reiterated its Geron GRN Market Outperform / Speculative Risk rating and $9 price target in a research report published today. In the report, Rodman & Renshaw states, "With the spinal cord injury trial enrolling, a broad Phase 2 program for Imetelstat underway, and partnerships with GE Healthcare and AngioChem, we believe Geron represents an attractive opportunity for the risk-oriented, long-term investor." Shares of Geron were trading at $3.60 at the time of posting, down 3.61% from Monday's market close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!